1	Site-specific DNA methylation in KCNJ11 promoter
2	contributes to type 2 diabetes
3	
4	Mengmeng Zhu <sup>a,b,1</sup> , Qiaoliang Huang <sup>c,1</sup> , Heng Li <sup>a</sup> , Yujie Zhao <sup>a</sup> , Heming
5	Guo <sup>b</sup> , Tao Wang <sup>b</sup> , Xiaodan Liu <sup>b</sup> , Yun Huang <sup>b</sup> , Ji Hu <sup>b</sup> , Chen Fang <sup>b,*</sup> , Jian
6	Huang <sup>a*</sup>
7	
8	<sup>a</sup> School of Biology & Basic Medical Science, Soochow University, Suzhou,
9	Jiangsu 215123, China.
10	<sup>b</sup> Department of Endocrinology, The Second Affiliated Hospital of Soochow
11	University, Suzhou, Jiangsu 215004, China
12	$^{\rm c}$ Suzhou Center for Disease Control and Prevention, Suzhou , Jiangsu
13 14 15 16 17	215000, China
18	<sup>1</sup> These authors contributed equally to this work
19	*Corresponding authors
20	
21	Fang, C. E-mail: <u>afa9911@sina.com</u>
22	Huang, J. E-mail: <u>huangjian79@suda.edu.cn</u>
23 24 25 26 27 28 29 30 31 32 33	

34

## 35 Abstract

Aims: This study explores the correlation between site-specific methylation levels of the KCNJ11 promoter and type 2 diabetes mellitus (T2DM), analyzing potential molecular mechanisms.

Methods: Thirty patients newly diagnosed with T2DM and 30 healthy controls were selected to determine the CpG methylation levels in the promoter region of the KCNJ11 gene using the bisulfite assay. The online software JASPAR was used to predict transcription factors binding to differentially methylated sites. Key transcription factors were further validated through quantitative PCR (q-PCR) and chromatin immunoprecipitation followed by PCR (ChIP-PCR).

**Results:** Methylation at multiple CpG sites within the KCNJ11 gene promoter was significantly reduced in newly diagnosed T2DM patients compared to healthy individuals. The methylation status of CpG-471, a site crucial for the binding of the transcription factor TCF12, emerged as potentially influential in T2DM pathogenesis. This reduction in methylation at CpG-471 may enhance TCF12 binding, thereby altering KCNJ11 expression.

52 **Conclusion:** Hypomethylation of specific CpG sites in the promoter region 53 of the KCNJ11 gene in patients with incipient T2DM potentially contributes to 54 the disease's pathogenesis. This hypomethylation enhances the 55 transcriptional activity of TCF12, which binds to these sites, possibly 56 influencing regulatory pathways involved in pancreatic beta-cell function.

## 57 Keywords

58 Type 2 diabetes; DNA methylation; KCNJ11 gene; TCF12 transcription factor

59

#### 60 **1. Introduction**

61 Type 2 diabetes mellitus (T2DM) is a complex polygenic disease[1], primarily 62 driven by insulin resistance and inadequate insulin production from  $\beta$  cells[2]. 63 According to the updated version of the International Diabetes Federation 64 (IDF) Diabetes Atlas, more than 500 million patients worldwide have diabetes, 65 and this number is expected to increase by 20% by 2030 and 46% by 2045[3]. 66 China has the highest prevalence of diabetes and prediabetes, with an 67 estimated 10.9% of Chinese adults diagnosed with diabetes and 35.7% with 68 prediabetes[4]. Due to the significant increase in the incidence of T2DM and 69 its concomitant acute and chronic complications, it is an important cause of 70 patient death and increased healthcare costs, which brings a huge economic 71 burden to the society, and there is an urgent need to actively intervene in the 72 treatment of T2DM from the etiologic and early prevention perspectives[5, 6]. 73 The etiology of T2DM is complex, resulting from a combination of genetic and 74 environmental factors[7]. An important area of current research is the search 75 for reliable, sensitive and easily accessible biomarkers for T2DM. In this 76 context, a growing number of studies[8-13]suggest that genetic and epigenetic mechanisms together play an important role in the pathogenesis of 77 78 T2DM patients.

79

Differential variability in DNA methylation, often indicative of epigenetic 80 81 dysregulation, is associated with various phenotypes, pathologies, and 82 adverse environments[9]. Initial epigenetic studies in pancreatic islets and 83 skeletal muscle of T2DM patients identified altered methylation 84 patterns[14].Recent genome-wide DNA methylation studies have confirmed 85 these findings, revealing altered methylation levels in diabetes-associated 86 genes like TCF7L2[15], PDX-1[16], CDKN1A[17], FTO[18], and 87 PPARGC1A[19], with changes in their promoter regions correlating with

88 diabetes risk and severity. Additionally, the KCNJ11 gene, encoding the Kir6.2 89 subunit of the ATP-sensitive K+ channel crucial for insulin secretion, has been 90 linked to T2DM development through both genetic mutations and methylation 91 changes[20-28]. Research has shown that methylation patterns of KCNJ11 92 vary by geography and ethnicity, with significant differences observed 93 between Indian and European T2DM populations[29]. These findings highlight 94 the complex interplay of genetic and epigenetic factors in T2DM, emphasizing 95 the potential of methylation studies in understanding and addressing this widespread disease. 96

97

98 While genome-wide association studies have extensively documented 99 changes in methylation patterns, few have focused on methylation at specific 100 sites. Therefore, our study aims to investigate the correlation between specific 101 methylation sites in the KCNJ11 gene promoter and the onset of Type 2 102 Diabetes Mellitus (T2DM), as well as how these modifications affect gene 103 expression through transcription factor regulation. Supporting literature 104 suggests that age-related methylation changes detectable in blood could 105 serve as biomarkers for T2DM[30-32]. To this end, we selected 30 patients 106 newly diagnosed with T2DM (20 men and 10 women), average age 57.0  $\pm$ 107 13.1 years. We also recruited 30 matched controls—18 males and 12 females, 108 average age 56.7 ± 10.1 years, all meeting specific criteria for glucose 109 tolerance. Exclusion criteria were a prior diabetes diagnosis, serious 110 concurrent conditions, pregnancy, and dropout from follow-up. Comparisons 111 between baseline data of the two groups showed no significant differences (P > 112 0.05), confirming their comparability. Preliminary results indicate significantly 113 decreased methylation at several sites within the KCNJ11 promoter in T2DM 114 patients compared to controls, particularly at CpG-471—a site crucial for 115 TCF12 binding—highlighting its potential role in T2DM pathogenesis.

116

#### 117 **2. Materials and methods**

## 118 2.1. Sample collection

119 After receiving approval from the Institutional Ethics Committee, blood 120 samples were collected from 30 newly diagnosed patients with T2DM at the 121 Department of Endocrinology, Second Affiliated Hospital of Soochow 122 University, and 30 healthy volunteers between November 2022 and 123 November 2023. Samples were drawn from the patients' arm veins using 124 disposable sterile syringes and stored in EDTA-containing tubes to prevent 125 coagulation. Collection occurred after an overnight fast, adhering to the WHO 126 1999 diagnostic criteria. Patients were informed and voluntarily participated in 127 the study as advised by their physicians.

### 128 2.2. DNA extraction

DNA extraction was performed using the TIANamp Genomic DNA kit (DP304; TIANGEN, Germany) according to the manufacturer's standard procedure. Genomic DNA was isolated from 200 µl of the collected peripheral blood samples. The purity of the DNA samples was assessed by calculating the absorbance ratio at 260 nm to 280 nm using an Invitrogen Nanodrop spectrophotometer. The isolated DNA samples were stored at -80°C for further analysis.

#### 136 **2.3. McrBC-PCR analysis**

137 McrBC is a GTP-dependent specific nucleic acid endonuclease that acts on 138 methylcytosine-containing DNA and does not act on unmethylated DNA[33]. 139 The DNA methylation level of the region upstream of the KCNJ11 transcription 140 start site was detected by McrBC-PCR. McrBC digestion was performed with 141 at least 200 ng of genomic DNA using the McrBC kit (M0272S; NEB) 142 according to the manufacturer's instructions. The same amount of DNA 143 without McrBC digestion was used as a negative control. Primers were 144 designed using Primer3, sequences of primers used for McrBC PCR are listed

in Supplementary Table 1, 50ul of the PCR amplification system was usedand the products were analyzed by electrophoresis on a 1.5% agarose gel.

147 **2.4.** Bisulfite sequencing PCR (BSP)

148 DNA Bisulfite Conversion Kit (E3318S; NEB) was applied to DNA bisulfite 149 modification according to the instructions. The total PCR system was  $50\mu$ L, to 150 which 6µL of bisulfate-modified DNA template, 25µL of 2×PCR buffer, 2µL 151 each of upstream and downstream primers were added, and the final volume 152 was adjusted to 50µL with double-distilled water. The PCR conditions and 153 setting reaction procedures were as follows: pre-denaturation at 94°C for 3 154 min, denaturation at 94°C for 30s, annealing at 55°C for 30s, and extension at 155 72°C for 16s for 35 cycles, and the reaction ended with a final extension at 72°C 156 for 7 min. The PCR products were electrophoresed in a 2% agarose gel, after 157 which the target fragments were recovered. The pMD18-T vector (6011, 158 TaKaRa) was used for TA clonal ligation, followed by transformation of DH5 $\alpha$ 159 receptor cells. Positive clones were selected and sent to AZENTA for 160 sequencing, and the methylation rate was calculated as the number of 161 methylated cytosine (mC) clones/10×100%. The sequencing results were 162 analyzed online according to Web-based Kismeth software (http://katahdin. 163 Mssm.edu/6ismet/revpage.pl)[34].

164

#### 165 **2.5.** Chromatin immunoprecipitation (ChIP) assay

166 ChIP assay was used to validate the binding of the transcription factor TCF12 167 to the promoter of the KCNJ11 gene. 293T cells were fixed with formaldehyde, 168 and glycine was added for cross-linking. The samples were then placed on ice 169 and sonicated to isolate DNA. Cell lysates were incubated overnight with 170 antibodies (anti-TCF12 antibody(sc-28364,Santa Cruz Biotechnology) or 171 control IgG) at a dilution of 1:50 and then with protein G-agarose beads 172 (#3956088, Merck KgaA, Germany) at 4°C overnight. Mouse control IgG

(#3452481, Merck KgaA, Germany) was used as a negative control for the
reaction. The bound DNA-protein mixture was eluted and the cross-linking
was reversed after several washes. The DNA fragments were then purified
and subjected to PCR with the KCNJ11 primer. The PCR products (172 bp)
were separated on a 2% agarose gel and visualized on a UV transilluminator.

178

# 179 2.6. Bioinformatic analysis

180 Short reads downloaded from the SRA database with accession SRP274496 181 were used to produce quality control reports through FastQC (https://www.bioi 182 nformatics.babraham.ac.uk/projects/fastqc/) and subjected to low-quality filteri 183 ng and adapter trimming using EtoKi (https://pubmed.ncbi.nlm.nih.gov/318092 184 57/). Clean data were aligned to the reference genome using Hisat2 (https://p 185 ubmed.ncbi.nlm.nih.gov/31375807/), and the mapped results were sorted usin 186 g Samtools (https://pubmed.ncbi.nlm.nih.gov/19505943/). Transcriptome asse 187 mbly and counting were carried out using StringTie (https://pubmed.ncbi.nlm.n 188 ih.gov/25690850/). Bioinformatic analysis was performed using the R comman 189 d line, and differential expression analysis was conducted using edgeR (https://www.ntline.com/https 190 //pubmed.ncbi.nlm.nih.gov/19910308/). R packages pheatmap (https://cran.r-191 project.org/web/packages/pheatmap/index.html) were used for visualization. 192

193 **2.7.** Quantitative real time polymerase chain reaction assay

Peripheral blood leukocyte RNA was extracted with TRIzol <sup>™</sup> Reagent 194 195 (15596026CN, Thermo Fisher Scientific), and reverse transcription was 196 performed according to the instructions of the HiScript II Q RT SuperMix for 197 qPCR(+gDNA wiper)(R223,Vazyme) kit. The total volume of the QPCR 198 amplification mixture was 10µL, and 1µL of cDNA template, 5µL of 2\*ChamQ 199 SYBR gPCR Master Mix (Q341,Vazyme,), and 0.2µL of upstream and 200 downstream primers were added. The volume was adjusted to a final volume 201 of 10µL with double-distilled water. The PCR conditions and the setup of the

202 reaction program were as follows: pre-denaturation at 95 °C for 180s,

203 denaturation at 95°C for 15s, and annealing and extension at 60°C for 60s,

and the reaction was run for 39 cycles.

205

## 206 **2.8.** Statistical analysis

The data are presented as the mean  $\pm$  SD. Differences in mean values between two groups were analyzed using the two-tailed t-test. Statistical analyses were performed using the GraphPad Prism version 6.0 (GraphPad Software, USA). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 or \*\*\*\*p < 0.0001 were considered statistically significant.

212

## 213 **3. Results**

214

## 215 **3.1.** Clinical characteristics of the study population

216 To maintain a consistent genetic background and characterize the course of 217 the disease, several potential confounders were considered in this study 218 based on the literature and clinical judgment. Covariates included age, sex, 219 body mass index, smoking status, alcohol consumption status, family history, 220 physical activity, creatinine, total cholesterol, triglyceride, and low-density 221 lipoprotein levels of the included subjects. The data included in this study 222 were categorized into two types of continuous and categorical variables. 223 Continuous variables are expressed as the mean ± standard deviation and 224 were subjected to t-test (normal distribution) or Kruskal-Wallis rank sum test 225 (non-normal distribution) depending on the normality of the distribution; 226 categorical variables were expressed as percentages and were subjected to 227 the x2 test (**Table 1**). The subjects were divided into a healthy control group 228 and a first-onset type 2 diabetes group according to the WHO 1999 diabetes 229 diagnostic criteria. After the application of strict inclusion criteria, Table 1 230 shows that the differences between the two groups were statistically

significant only for fasting blood glucose, two-hour postprandial blood glucose,

and glycosylated hemoglobin(P<0.001).

233

## 234 **3.2. McrBC-PCR analysis**

Agarose gel electrophoresis of the PCR products of diabetic and healthy control samples with the same amount of DNA before and after 1h of McrBC digestion and analysis of gray values are shown in (**Fig. 1**). The results demonstrated that DNA methylation modification exists in the promoter region of the KCNJ11 gene in patients with first-onset T2DM and healthy controls, and that the degree of methylation modification in healthy control samples is likely to be greater than that in patients with first-onset T2DM.

242

3.3. BSP results confirm differences in site-specific methylation of the
 KCNJ11 promoter region between healthy controls and patients with
 first-onset T2DM

We analyzed DNA methylation at selected locations in this region in the healthy and T2DM groups using the bisulfite sequencing method, as shown in Figure 2B, and the results based on Kismeth software analysis showed an overall decrease in cytosine methylation levels from 22.22% to 3.33%.

250

251 Moreover, after bisulfite modification treatment and sequencing of positive 252 clones, it was demonstrated that there were methylation sites at nine sites, 253 including CpG-449, CpG-454, CpG-471, CpG-499, CpG-504, CpG-510, CpG-254 513, CpG-520, and CpG-539. The methylation ratios of the above loci were 255 significantly lower in patients in the type 2 diabetes group, whereas they were 256 hypermethylated in the healthy normal control group. Moreover, at the CpG-257 471 locus, the methylation rate was decreased by approximately 7.55% in the 258 T2DM group compared with that in the healthy control group (Fig. 2C).

259

260 **3.4.** Binding of differentially methylated sites in the promoter region of

## the KCNJ11 gene to the transcription factor TCF12

262 DNA methylation has been extensively studied over the past few decades, 263 and the attachment of methyl groups to the promoter region of a gene might 264 inhibit transcription factor binding, and hence usually reduce transcription; the 265 opposite phenomenon also holds true[35, 36]. The results analyzed by 266 JASPAR and AlphaFold online software showed that the presence of TCF12 267 transcription factor binds to the promoter region of the KCNJ11 gene near the differentially 268 methylated site CpG-471, which may explain the 269 hypomethylation of the KCNJ11 promoter region in patients with T2DM, which 270 can affect protein expression by enhancing the activity of the transcription 271 factor TCF12 and thus predispose them to developing T2DM (Fig. 3A). CHIP-272 PCR gel electrophoresis revealed target bands in the input group and anti-273 TCF12 group but no bands in the IgG or blank group (Fig. 3B), which also 274 confirmed that the transcription factor TCF12 binds to the promoter region of 275 the KCNJ11 gene and may be involved in the methylation changes at specific 276 loci of the KCNJ11 gene, possibly influencing the regulatory pathways 277 involved in pancreatic beta-cell function.

278

#### 279 **3.5. KCNJ11 expression in human peripheral blood**

The RNA-seq data from 12 blood samples obtained from the SRA database, 280 281 including 6 from healthy individuals and 6 from type 2 diabetes patients, were 282 included in the analysis. Differential gene expression analysis revealed that 283 the KCNJ11 gene was upregulated in the type 2 diabetes group (logFC = 284 1.478151, p = 0.09869249, FDR = 0.3574878) (Fig. 4A). We then extracted 285 RNA from fresh peripheral blood of enrolled healthy controls and T2DM 286 patients for semi-quantitative analysis of the KCNJ11 gene, and the results 287 demonstrated that KCNJ11 mRNA expression was increased in peripheral 288 blood from patients with T2DM compared with that in peripheral blood from 289 healthy controls (p < 0.001) (Fig. 4B).

290

## 291 4. Discussion

In this study, BSP-sequencing was utilized to examine methylation levels at specific sites within the KCNJ11 gene promoter in blood samples from individuals at the early stages of Type 2 Diabetes Mellitus (T2DM). Employing bisulfite conversion, a well-established technique for DNA cytosine methylation analysis[37], our results demonstrated distinct differences in methylation patterns at several critical sites between newly diagnosed T2DM patients and healthy controls.

299 The current literature establishes a clear link between DNA methylation at 300 gene promoters, CpG islands, and proximal gene body sites with changes in 301 transcriptional activity and gene expression[38, 39]. Our findings reinforce this 302 paradigm, revealing significant hypomethylation at pivotal sites within the 303 KCNJ11 promoter in T2DM subjects. This epigenetic alteration likely facilitates 304 increased binding of the transcription factor TCF12, potentially augmenting 305 protein expression and, consequently, T2DM susceptibility. This observation 306 underscores the therapeutic potential of targeting TCF12, not only enhancing 307 our understanding of its regulatory mechanisms but also promoting it as a 308 viable target for T2DM treatment.

309 Research within the diabetes field is predominantly focused on two 310 approaches: comprehensive scans for differential DNA methylation across the 311 genome[40] and targeted investigations into known diabetes-associated 312 genes using specific primers to pinpoint differential methylation[15, 16, 41, 42]. 313 Our study's focus on the KCNJ11 promoter methylation contributes 314 significantly to the broader epigenetic narrative of T2DM pathogenesis, paving 315 the way for novel insights into disease mechanisms and therapeutic 316 innovation[43]. The role of methylation in other gene loci related to diabetes 317 progression remains an open question warranting further exploration.

318 With diabetes prevalence increasing globally, the imperative for innovative 319 therapeutic approaches is more pressing than ever. Future treatment

320 modalities might include epigenetic editing of specific genes[44], a strategy 321 supported by emerging research advocating for targeting the enzymes that 322 modify epigenetic landscapes in tissues affected by diabetes[45, 46]. 323 Moreover, epigenetic changes in diabetic patients have been increasingly 324 associated with severe vascular complications, such as retinopathy, stroke, 325 and myocardial infarction[47-49]. Identifying epigenetic biomarkers, readily 326 detectable in blood and derivative from target tissues, could profoundly impact 327 clinical practices by facilitating easier analysis in diabetic and at-risk 328 populations. However, the discovery of epigenetic markers with superior 329 predictive strength over existing diabetes indicators remains a critical 330 research need.

In summary, our study has identified significant epigenetic modifications in the promoter of the KCNJ11 gene in patients with T2DM, highlighting a robust link between epigenetics and the pathophysiology of diabetes in humans. These epigenetic markers offer promising avenues as biomarkers for predicting T2DM, gauging the risk of vascular complications, and assessing the efficacy of therapeutic and lifestyle interventions, thus heralding a new era of precision medicine in diabetes care.

#### 338 Acknowledgements

This research was supported by grants from the National Natural Science Foundation of China (82371544,82070814); Suzhou Healthcare Science and Technology Innovation Program (SKYD2022030); Open project of Jiangsu Health Development Research Center (JSHD2022035); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

## 345 **Conflict of interest**

346 None declared.

347	
348	
349	
350	
351	
352	REFERENCES
353	[1]. Gloyn AL, McCarthy MI. The genetics of type 2 diabetes. Best Pract Res
354	Clin Endocrinol Metab. 2001;15:293-308. <u>http://dx.doi.org/10.1053/beem.2</u>
355	<u>001.0147</u>
356	[2]. Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013;
357	36:1047-55.http://dx.doi.org/10.2337/dc12-1805
358	[3]. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, e
359	t al. IDF Diabetes Atlas: Global, regional and country-level diabetes preva
360	lence estimates for 2021 and projections for 2045. Diabetes Res Clin Pra
361	ct. 2022;183:109119. <u>http://dx.doi.org/10.1016/j.diabres.2021.109119</u>
362	[4]. Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, et al. Prevalence
363	and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA.
364	2017;317:2515-23. <u>http://dx.doi.org/10.1001/jama.2017.7596</u>
365	[5]. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 dia
366	betes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88-98.
367	http://dx.doi.org/10.1038/nrendo.2017.151
368	[6]. Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating typ
369	e 2 diabetes and diabetic complications. Am J Prev Med. 2013;45:253-61.
370	http://dx.doi.org/10.1016/j.amepre.2013.04.017
371	[7]. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century.
372	World J Diabetes. 2015;6:850-67. <u>http://dx.doi.org/10.4239/wjd.v6.i6.850</u>
373	[8]. Bernstein D, Golson ML, Kaestner KH. Epigenetic control of beta-cell func
374	tion and failure. Diabetes Res Clin Pract. 2017;123:24-36. <u>http://dx.doi.org</u>
375	<u>/10.1016/j.diabres.2016.11.009</u>
376	[9]. Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell
377	Metab. 2019;29:1028-44. <u>http://dx.doi.org/10.1016/j.cmet.2019.03.009</u>
378	[10]. Wren JD, Garner HR. Data-mining analysis suggests an epigenetic path
379	ogenesis for type 2 diabetes. J Biomed Biotechnol. 2005;2005:104-12. <u>htt</u>
380	p://dx.doi.org/10.1155/JBB.2005.104
381	[11]. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 201
382	0;363:2339-50.http://dx.doi.org/10.1056/NEJMra0906948
383	[12]. Ling C, Groop L. Epigenetics: a molecular link between environmental fa
384	ctors and type 2 diabetes. Diabetes. 2009;58:2718-25.http://dx.doi.org/10.
385	2337/db09-1003
386	[13]. Ronn T, Ling C. DNA methylation as a diagnostic and therapeutic target i
387	n the battle against Type 2 diabetes. Epigenomics. 2015;7:451-60. <u>http://d</u>
388	x.doi.org/10.2217/epi.15.7
389	[14]. Barres R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, et al. Non-CpG m

000	othylation of the DCC delpha areaster through DNMT2D controls without
390	enviation of the PGC-faipha promoter through Divid 3B controls mitoch
391	ondrial density. Cell Metab. 2009;10:189-98. <u>nttp://dx.doi.org/10.1016/j.cm</u>
392	<u>et.2009.07.011</u>
393	[15]. Small HO, Monamad DA. Identification of DNA methylation change in TC
394	F/L2 gene in the blood of type 2 diabetes mellitus as a predictive biomar
395	ker in Iraq Kurdistan region by using methylation-specific PCR. Endocr R
396	egul. 2023;57:53-60. <u>http://dx.doi.org/10.2478/enr-2023-0007</u>
397	[16]. Yang BT, Dayeh TA, Volkov PA, Kirkpatrick CL, Malmgren S, Jing X, et al.
398	Increased DNA methylation and decreased expression of PDX-1 in pancr
399	eatic islets from patients with type 2 diabetes. Mol Endocrinol. 2012;26:12
400	03-12. <u>http://dx.doi.org/10.1210/me.2012-1004</u>
401	[17]. Dayeh T, Volkov P, Salo S, Hall E, Nilsson E, Olsson AH, et al. Genome-
402	wide DNA methylation analysis of human pancreatic islets from type 2 dia
403	betic and non-diabetic donors identifies candidate genes that influence in
404	sulin secretion. PLoS Genet. 2014;10:e1004160. <u>http://dx.doi.org/10.1371</u>
405	<u>/journal.pgen.1004160</u>
406	[18]. Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, et al.
407	Genome-wide survey reveals predisposing diabetes type 2-related DNA
408	methylation variations in human peripheral blood. Hum Mol Genet. 2012;
409	21:371-83.http://dx.doi.org/10.1093/hmg/ddr472
410	[19]. Ling C, Del Guerra S, Lupi R, Ronn T, Granhall C, Luthman H, et al. Epig
411	enetic regulation of PPARGC1A in human type 2 diabetic islets and effect
412	on insulin secretion. Diabetologia. 2008;51:615-22. <u>http://dx.doi.org/10.10</u>
413	<u>07/s00125-007-0916-5</u>
414	[20]. Dreszer TR, Karolchik D, Zweig AS, Hinrichs AS, Raney BJ, Kuhn RM, et
415	al. The UCSC Genome Browser database: extensions and updates 2011.
416	Nucleic Acids Res. 2012;40:D918-23. <u>http://dx.doi.org/10.1093/nar/gkr10</u>
417	<u>55</u>
418	[21]. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin
419	secretion. J Clin Invest. 2005;115:2047-58. <u>http://dx.doi.org/10.1172/JCl25</u>
420	<u>495</u>
421	[22]. Inagaki N, Gonoi T, Clement JPt, Namba N, Inazawa J, Gonzalez G, et al.
422	Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea
423	receptor. Science. 1995;270:1166-70.http://dx.doi.org/10.1126/science.27
424	<u>0.5239.1166</u>
425	[23]. Wieland I, Schanze I, Felgendreher IM, Barthlen W, Vogelgesang S, Moh
426	nike K, et al. Integration of genomic analysis and transcript expression of
427	ABCC8 and KCNJ11 in focal form of congenital hyperinsulinism. Front En
428	docrinol (Lausanne). 2022;13:1015244. <u>http://dx.doi.org/10.3389/fendo.20</u>
429	<u>22.1015244</u>
430	[24].Tarasov AI, Welters HJ, Senkel S, Ryffel GU, Hattersley AT, Morgan NG,
431	et al. A Kir6.2 mutation causing neonatal diabetes impairs electrical activit
432	y and insulin secretion from INS-1 beta-cells. Diabetes. 2006;55:3075-82.
433	http://dx.doi.org/10.2337/db06-0637

434 [25]. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, 435 et al. Activating mutations in the gene encoding the ATP-sensitive potassi 436 um-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J M 437 ed. 2004;350:1838-49.http://dx.doi.org/10.1056/NEJMoa032922 438 [26]. Schwanstecher C, Meyer U, Schwanstecher M. K(IR)6.2 polymorphism p redisposes to type 2 diabetes by inducing overactivity of pancreatic beta-439 440 cell ATP-sensitive K(+) channels. Diabetes. 2002;51:875-9.http://dx.doi.or 441 g/10.2337/diabetes.51.3.875 [27]. Schwanstecher C, Neugebauer B, Schulz M, Schwanstecher M. The co 442 443 mmon single nucleotide polymorphism E23K in K(IR)6.2 sensitizes pancr eatic beta-cell ATP-sensitive potassium channels toward activation throug 444 h nucleoside diphosphates. Diabetes. 2002;51 Suppl 3:S363-7.http://dx.d 445 446 oi.org/10.2337/diabetes.51.2007.s363 [28]. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, Cline MS, et al. 447 448 The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 449 2011;39:D876-82.http://dx.doi.org/10.1093/nar/gkq963 [29]. Elliott HR, Walia GK, Duggirala A, Groom A, Reddy SU, Chandak GR, et 450 451 al. Migration and DNA methylation: a comparison of methylation patterns i 452 n type 2 diabetes susceptibility genes between indians and europeans. J Diabetes Res Clin Metab. 2013;2:6.http://dx.doi.org/10.7243/2050-0866-2 453 454 -6 [30]. Bacos K, Gillberg L, Volkov P, Olsson AH, Hansen T, Pedersen O, et al. 455 Blood-based biomarkers of age-associated epigenetic changes in human 456 457 islets associate with insulin secretion and diabetes. Nat Commun. 2016;7: 458 11089.http://dx.doi.org/10.1038/ncomms11089 459 [31]. Bysani M, Perfilyev A, de Mello VD, Ronn T, Nilsson E, Pihlajamaki J, et 460 al. Epigenetic alterations in blood mirror age-associated DNA methylation 461 and gene expression changes in human liver. Epigenomics. 2017;9:105-22.http://dx.doi.org/10.2217/epi-2016-0087 462 [32]. Ronn T, Volkov P, Gillberg L, Kokosar M, Perfilyev A, Jacobsen AL, et al. 463 464 Impact of age, BMI and HbA1c levels on the genome-wide DNA methylati on and mRNA expression patterns in human adipose tissue and identifica 465 tion of epigenetic biomarkers in blood. Hum Mol Genet. 2015;24:3792-81 466 467 3.http://dx.doi.org/10.1093/hmg/ddv124 [33]. Sutherland E, Coe L, Raleigh EA. McrBC: a multisubunit GTP-dependent 468 469 restriction endonuclease. J Mol Biol. 1992;225:327-48.http://dx.doi.org/1 470 0.1016/0022-2836(92)90925-a [34]. Gruntman E, Qi Y, Slotkin RK, Roeder T, Martienssen RA, Sachidananda 471 m R. Kismeth: analyzer of plant methylation states through bisulfite seque 472 ncing. BMC Bioinformatics. 2008;9:371.http://dx.doi.org/10.1186/1471-21 473 05-9-371 474 475 [35]. Volkov P, Bacos K, Ofori JK, Esguerra JL, Eliasson L, Ronn T, et al. Whol 476 e-Genome Bisulfite Sequencing of Human Pancreatic Islets Reveals Nov 477 el Differentially Methylated Regions in Type 2 Diabetes Pathogenesis. Dia

478	betes. 2017;66:1074-85.http://dx.doi.org/10.2337/db16-0996
479	[36]. Jones PA. Functions of DNA methylation: islands, start sites, gene bodie
480	s and beyond. Nat Rev Genet. 2012;13:484-92.http://dx.doi.org/10.1038/
481	nrg3230
482	[37], Gouil Q. Keniry A. Latest techniques to study DNA methylation. Essays B
483	iochem. 2019:63:639-48.http://dx.doi.org/10.1042/EBC20190027
484	[38], Yang X, Han H, De Carvalho DD, Lav FD, Jones PA, Liang G, Gene bod
485	v methylation can alter gene expression and is a therapeutic target in can
486	cer. Cancer Cell. 2014:26:577-90.http://dx.doi.org/10.1016/i.ccr.2014.07.0
487	28
488	[39], Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onvango P, et al.
489	The human colon cancer methylome shows similar hypo- and hypermeth
490	vlation at conserved tissue-specific CpG island shores. Nat Genet. 2009:
491	41:178-86.http://dx.doi.org/10.1038/ng.298
492	[40]. Volkmar M, Dedeurwaerder S, Cunha DA, Ndlovu MN, Defrance M, Depl
493	us R, et al. DNA methylation profiling identifies epigenetic dysregulation i
494	n pancreatic islets from type 2 diabetic patients. EMBO J. 2012;31:1405-
495	26.http://dx.doi.org/10.1038/emboj.2011.503
496	[41]. Fatima N, Schooley JF, Jr., Claycomb WC, Flagg TP. Promoter DNA met
497	hylation regulates murine SUR1 (Abcc8) and SUR2 (Abcc9) expression i
498	n HL-1 cardiomyocytes. PLoS One. 2012;7:e41533.http://dx.doi.org/10.13
499	71/journal.pone.0041533
500	[42]. Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, et al. I
501	nsulin promoter DNA methylation correlates negatively with insulin gene e
502	xpression and positively with HbA(1c) levels in human pancreatic islets. D
503	iabetologia. 2011;54:360-7.http://dx.doi.org/10.1007/s00125-010-1967-6
504	[43]. Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. Genetics of type 2 d
505	iabetes mellitus and other specific types of diabetes; its role in treatment
506	modalities. Diabetes Metab Syndr. 2012;6:54-8.http://dx.doi.org/10.1016/j.
507	<u>dsx.2012.05.014</u>
508	[44]. Chen H, Kazemier HG, de Groote ML, Ruiters MH, Xu GL, Rots MG. Ind
509	uced DNA demethylation by targeting Ten-Eleven Translocation 2 to the h
510	uman ICAM-1 promoter. Nucleic Acids Res. 2014;42:1563-74.http://dx.doi.
511	org/10.1093/nar/gkt1019
512	[45]. Christensen DP, Dahllof M, Lundh M, Rasmussen DN, Nielsen MD, Billes
513	trup N, et al. Histone deacetylase (HDAC) inhibition as a novel treatment
514	for diabetes mellitus. Mol Med. 2011;17:378-90.http://dx.doi.org/10.2119/
515	molmed.2011.00021
516	[46]. Christensen DP, Gysemans C, Lundh M, Dahllof MS, Noesgaard D, Sch
517	midt SF, et al. Lysine deacetylase inhibition prevents diabetes by chromat
518	in-independent immunoregulation and beta-cell protection. Proc Natl Aca
519	d Sci U S A. 2014;111:1055-9. <u>http://dx.doi.org/10.1073/pnas.1320850111</u>
520	[47]. Agardh E, Lundstig A, Perfilyev A, Volkov P, Freiburghaus T, Lindholm E,
521	et al. Genome-wide analysis of DNA methylation in subjects with type 1 di

522 523	abetes identifies epigenetic modifications associated with proliferative dia betic retinopathy. BMC Med. 2015;13:182. <u>http://dx.doi.org/10.1186/s1291</u>
524 525 526 527 528	<ul> <li>[48]. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, et al. E pigenomic profiling reveals an association between persistence of DNA m ethylation and metabolic memory in the DCCT/EDIC type 1 diabetes coh ort. Proc Natl Acad Sci U S A. 2016;113:E3002-11.<u>http://dx.doi.org/10.107</u></li> </ul>
529	<u>3/pnas.1603712113</u>
530	[49]. Nakatochi M, Ichihara S, Yamamoto K, Naruse K, Yokota S, Asano H, et
531	al. Epigenome-wide association of myocardial infarction with DNA methyl
532	ation sites at loci related to cardiovascular disease. Clin Epigenetics. 201
533	7;9:54. <u>http://dx.doi.org/10.1186/s13148-017-0353-3</u>
534	
535	
536	
537	
538	
539	
540	
541	
542	
543	
544	
545	
546	
547	
548	
549	

550			
551			
552			
553			
554			
555			
556			
557			
558			
559			
560			
561			
562			
563			
564			
565			
566			
567			
568			
569			
570			
571			

_	70
5	1.1

Table 1 -					
TABLE 1. Clinical Characteristics of the subjects					
Parameters	Healthy controls	T2DM	P value		
n (male/female)	30(20/10)	30(18/12)			
Age (year)	56.7±10.1	57.0±13.1	1		
BMI (kg/m2 )	25.9±3.6	28.5±4.7	0.13		
HbA1c(%)	5.7±0.8	7.3±1.2	0.00010		
FBG(mmol/L)	4.9±0.5	8.3±1.1	0.00010		
PBG (mmol/L)	6.8±0.6	12.4±0.5	0.00010		
Family history	4(13.3%)	8(26.67%)	0.36		
Smoking	5(16.67%)	7(23.33%)	0.747		
Alcohol	5(16.67%)	9(30%)	0.36		
Physical activity	12(40%)	10(33.33%)	0.789		
Scr (umol/L)	95.51±0.4	96.35±0.6	0.763		
TG(mmol/l)	1.54±0.3	1.59±0.5	0.543		
TC(mmol/l)	4.34±0.2	4.39±0.4	0.893		
LDL-C(mmol/L)	2.83±0.25	2.86±0.34	0.895		
Data are presen	Data are presented as mean ± standard deviation or as a number (%) of				
participants. Krus	participants. Kruskal Wallis test was used for statistical analysis. Abbreviations:				

575 BMI - body mass index; HbA1c - hemoglobin A1c; FBG - fasting blood

576 glucose; PBG - postprandial blood glucose; Scr - serum creatinine; TG -

577 triglyceride; TC - serum total cholesterol; LDL-C - low-density lipoprotein

- 578 cholesterol; p statistical significance.



Gel electrophoresis of different diabetic samples and healthy subjects after
1h digestion by McrBC. The same amount of DNA from the same sample
on the left side is the uncut control, and on the right side is the digestion
for 1h (A); The below panel shows the bar graph of gray value analysis (B).
Abbreviations: U – undigested; M – McrBC digested; P – patient; C –
healthy control.



612

# 613 **FIG. 2.**

614	Schematic illustration of the amplification positions of each primer pair in
615	the promoter region of KCNJ11 and the binding site of the TCF12
616	transcription factor.P1 represents the MCrBC primer (668bp), P2
617	represents the BSP primer (151bp), and P3 represents the CHIP primer
618	(172bp)(A).Healthy control and T2DM genomic DNA were sequenced for
619	different clones after treatment with sodium bisulfite, and scatters
620	represent cytosines at the positions indicated in the KCNJ11 5' region , $^{\ast}$
621	labeled at the CpG-471 site (B).Histogram of the methylation rate of the
622	KCNJ11 promoter region in the first-episode T2DM group (red bars) and
623	healthy control group(blue bars) (C) . Abbreviations: P - primer; F -
624	forward; R – reverse.
625	
626	
627	
628	
629	
630	
631	
632	
633	
634	
635	
636	

637			
638			
639			
640			
641			
642			
643			
644			
645			
646			
647			
648			
649			
650			
651			
652			
653			
654			
655			
656			



- 676





694 (A). KCNJ11 mRNA expression levels in human peripheral blood from

- healthy controls and patients with T2DM. Gene expression was analyzed
- using quantitative RT-PCR. The results are expressed as the mean ± SD
- 697 (B).